Trial of Psilocybin versus Escitalopram for Depression.

  title={Trial of Psilocybin versus Escitalopram for Depression.},
  author={Robin Lester Carhart-Harris and Bruna Giribaldi and Rosalind Watts and Michelle Baker-Jones and Ashleigh Murphy-Beiner and Robert Murphy and Jonny Martell and Allan Blemings and David Erritzoe and David J. Nutt},
  journal={The New England journal of medicine},
  volume={384 15},
BACKGROUND Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. METHODS In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive two separate doses of 25 mg of… 

Figures and Tables from this paper

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.

In this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects.

A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression

Background: A trial of psilocybin (COMP360) versus escitalopram for major depressive disorder (MDD) was reported as negative, as there was no significant difference in the primary outcome, mean change

Effects of psilocybin versus escitalopram on rumination and thought suppression in depression

Background Major depressive disorder is often associated with maladaptive coping strategies, including rumination and thought suppression. Aims To assess the comparative effect of the selective

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

Background: Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known

Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review

This publication discusses two compounds belonging to the psychoactive substances group which are studied in the context of depression treatment—psilocybin and esketamine. The former is a naturally

Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review

Psilocybin-containing mushrooms have been consumed by various cultures in many different parts of the world for thousands of years. Psilocybin, a classic psychedelic, contains unique psychoactive

Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial

Psilocybin-assisted therapy may be a new treatment for major depressive disorder (MDD), with encouraging data from pilot trials, and this trial aimed to test the feasibility of a parallel-group, randomised, placebo-controlled design.

The therapeutic potential of psilocybin: a systematic review

The findings of these studies collectively show that psilocybin has a positive benefit–risk balance in the treatment of various mental disorders with an immediate and prolonged effect following 1–3 doses of p silocybin and a few (serious) adverse events.

Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression

Background: Across psychotherapeutic frameworks, the strength of the therapeutic alliance has been found to correlate with treatment outcomes; however, its role has never been formally assessed in a

Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review

Psilocybin represents a promising alternative in the treatment of depression and further research with larger sample sizes is needed to better understand the neurobiological factors of its effects and to investigate its potential for use in everyday practice.



Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort.

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Psilocybin was associated with enduring anxiolytic and anti-depressant effects in patients with cancer-related psychological distress, sustained benefits in existential distress and quality of life, as well as improved attitudes towards death.

Escitalopram versus other antidepressive agents for depression.

Some statistically significant differences favouring escITALopram over other antidepressive agents for the acute phase treatment of major depression were found, in terms of efficacy (citalopram and fluoxetine) and acceptability (duloxettine).

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

The view that the quality of the acute psychedelic experience is a key mediator of long-term changes in mental health is bolstered, as data from a clinical trial assessing psilocybin for treatment-resistant depression confirmed this.

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety and revealed a positive trend toward improved mood and anxiety.

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.